Andy Abril, MD, a lead author of the ACR/VF guideline for Takayasu arteritis (TAK), discusses the recommendations for TAK.
The Latest Psoriatic Arthritis Management Insights
An overview of the research to date and the ways in which such evidence can be used to guide the treatment of patients was presented at the 2019 ACR/ARP Annual Meeting in a session titled Optimizing Outcomes in Psoriatic Arthritis: A Domain-Based Strategy. In the years since this presentation, additional research has helped supply greater…
FDA Approves Avacopan for the Treatment of ANCA-Associated Vasculitis
On Oct. 8, ChemoCentryx Inc. announced that the U.S. Food & Drug Administration (FDA) has approved avacopan (TAVNEOS), an orally administered selective complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis), specifically granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) (the two main forms…
Fiscal Year 2022 ICD-10-CM Codes Now in Effect
New and updated FY22 diagnosis codes became effective for encounters on or after Oct. 1, 2021, including key updates for Sjögren syndrome and non-radiographic axial spondyloarthritis.
Guselkumab Promising in Patients with PsA
Initial 24-week data from a study of patients with psoriatic arthritis (PsA) show that treatment with guselkumab improved symptoms and resulted in a higher ACR20 response than placebo in patients who could not tolerate, or did not respond to, treatment with a tumor necrosis factor inhibitor (TNFi).
Dusty Trades: Inorganic Dust Exposure During Military Service May Be an Occupational Risk Factor for RA
Mounting evidence indicates that exposure to inorganic dust is a risk factor for the development of autoimmune diseases. According to a recent study, dust exposure during military service in dusty environments represents an occupational and environmental risk and was associated with a 10% increased risk of developing RA.
Severe COVID-19 May Trigger Autoimmunity
Reuters)—Severe COVID-19 may trick the immune system into producing autoantibodies that have the potential to eventually attack healthy tissue and cause inflammatory diseases, researchers warned in a paper published in Nature Communications.1 They found autoantibodies in blood samples from roughly 50% of the 147 COVID-19 patients they studied, but in fewer than 15% of 41…
Practical Ways to Manage Cardiovascular Risk in Patients with Psoriatic Arthritis
Increased cardiovascular (CV) risk in patients with rheumatic disease is old news. Over the past decade, a multitude of studies have demonstrated elevated CV risk in a variety of conditions: systemic lupus erythematosus, rheumatoid arthritis and psoriatic arthritis (PsA), to name a few. The risk in patients with rheumatic disease seems to be linked to…
The Role of ANA Positivity in Patients with RA
Recent research suggests patients with RA and a positive test for anti-nuclear antibody (ANA) may not have a different disease course than patients with RA who test negative for ANA. However, these patients may experience different treatment courses.
Nonserious Infection Rates with Biologics Used to Treat RA
Bechman et al. set out to describe the frequency and predictors of nonserious infections and compare incidence rates across biologic DMARDs. They found all bDMARDs are associated with a greater risk of nonserious infection, with differences observed between agents. Although unmeasured confounding must be considered, the magnitude of effect is large.
- « Previous Page
- 1
- …
- 58
- 59
- 60
- 61
- 62
- …
- 336
- Next Page »